These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26522590)

  • 1. Ulinastatin- and thymosin α1-based immunomodulatory strategy for sepsis: A meta-analysis.
    Han D; Shang W; Wang G; Sun L; Zhang Y; Wen H; Xu L
    Int Immunopharmacol; 2015 Dec; 29(2):377-382. PubMed ID: 26522590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
    Liu F; Wang HM; Wang T; Zhang YM; Zhu X
    BMC Infect Dis; 2016 Sep; 16():488. PubMed ID: 27633969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ulinastatin and/or thymosin α1 for severe sepsis: A systematic review and meta-analysis.
    Feng Z; Shi Q; Fan Y; Wang Q; Yin W
    J Trauma Acute Care Surg; 2016 Feb; 80(2):335-40. PubMed ID: 26517783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients.
    Liu D; Yu Z; Yin J; Chen Y; Zhang H; Xin F; Fu H; Wan B
    J Crit Care; 2017 Jun; 39():259-266. PubMed ID: 28069319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis.
    Li C; Bo L; Liu Q; Jin F
    Int J Infect Dis; 2015 Apr; 33():90-6. PubMed ID: 25532482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria.
    Zhang Y; Chen H; Li YM; Zheng SS; Chen YG; Li LJ; Zhou L; Xie HY; Praseedom RK
    J Infect Dis; 2008 Sep; 198(5):723-30. PubMed ID: 18613793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α1 for Sepsis: A Systematic Review and Meta-Analysis.
    Wang FY; Fang B; Qiang XH; Yu TO; Zhong JR; Cao J; Zhou LX
    Biomed Res Int; 2016; 2016():9508493. PubMed ID: 27340674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study.
    Chen H; He MY; Li YM
    Chin Med J (Engl); 2009 Apr; 122(8):883-8. PubMed ID: 19493408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical effects of ulinastatin and thymosin alpha1 on immune-modulation in septic patients].
    Su L; Meng FS; Tang YQ; Wen Q; Liu YS; Tang LQ; Duan PK; Luo RJ
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Mar; 21(3):147-50. PubMed ID: 19278583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of efficacy of thymosin alpha1 in the treatment of sepsis: a systematic review].
    Yu Y; Tian JH; Yang KH; Zhang P
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Jan; 21(1):21-4. PubMed ID: 19141185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1.
    Li Yumin ; Chen Hao ; Li Xun ; Zhou Wence ; He Minyan ; Chiriva-Internati M; Wachtel MS; Frezza EE
    J Intensive Care Med; 2009; 24(1):47-53. PubMed ID: 19033321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ulinastatin combined with thymosin α1 for treatment of severe sepsis: a histopathological observation in rats].
    Guo J; Deng Q; Guo X; Liu S; Zhang Y; He Z; Lin H
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(6):830-4. PubMed ID: 22699064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients.
    Liu D; Yu Z; Yin J; Chen Y; Zhang H; Fan X; Fu H; Wan B
    J Crit Care; 2017 Jun; 39():285-287. PubMed ID: 28283220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin].
    ; Lin HY
    Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(7):451-7. PubMed ID: 17459221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.
    Wu J; Zhou L; Liu J; Ma G; Kou Q; He Z; Chen J; Ou-Yang B; Chen M; Li Y; Wu X; Gu B; Chen L; Zou Z; Qiang X; Chen Y; Lin A; Zhang G; Guan X
    Crit Care; 2013 Jan; 17(1):R8. PubMed ID: 23327199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune and inflammation confusion in severe sepsis and effects of bi-immunomodulation therapy: a prospective, randomized, controlled clinical trial].
    Zhou LX; Tan JJ; Li YN; Luo HT; Shao YH; Qiang XH; Yu TO; Ma MY; Mao KJ; Fang B
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(15):1028-33. PubMed ID: 19595251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with thymosin alpha1 and dexamethasone helps mice survive sepsis.
    Xiang XS; Li N; Zhao YZ; Li QR; Li JS
    Inflammation; 2014 Apr; 37(2):402-16. PubMed ID: 24122349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Traditional Chinese medicine for septic patients undergoing ulinastatin therapy: A meta-analysis.
    Shan RF; Zhu YA; Qin J; Chen JP
    Medicine (Baltimore); 2021 Sep; 100(38):e27151. PubMed ID: 34559104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.
    Danielli R; Fonsatti E; Calabrò L; Di Giacomo AM; Maio M
    Ann N Y Acad Sci; 2012 Oct; 1270():8-12. PubMed ID: 23050811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xuebijing combined with ulinastation benefits patients with sepsis: A meta-analysis.
    Zheng J; Xiang X; Xiao B; Li H; Gong X; Yao S; Yuan T
    Am J Emerg Med; 2018 Mar; 36(3):480-487. PubMed ID: 29373169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.